According to new research by Flinders University, a common medicine that treats reflux, heartburn as well as ulcers can hinder the effectiveness of lung cancer immunotherapy medicines. The findings of this research were published in the 'British Journal of Cancer'. The study investigated the impact of proton pump inhibitors (PPIs) on patients undergoing treatment for non-small-cell lung cancer, the most common type of lung cancer, accounting for 85 per cent of cases. Lead author Dr Ash Hopkins from the Flinders Health and Medical Research Institute said it's important the impacts of PPIs are well understood. PPIs treat a number of stomach issues by reducing acid production in the wall of the stomach. Recent studies showed the medication can cause significant gut microbiota changes, which could lead to its impact on cancer immunotherapy.
Дата на публикация: 28 ноември, 2021
Категория:
Друго
Харесайте ни във Facebook